JP Morgan Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Day One Biopharmaceutical (NASDAQ:DAWN) and increased the price target from $32 to $36.
April 22, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama reaffirmed an Overweight rating on Day One Biopharmaceutical and raised the price target to $36 from $32.
The increase in price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100